Safety and pharmacokinetic (PK) study of perifosine plus capecitabine (P-CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC)

被引：1
|
作者：
Greco, F. A.
Infante, J. R.
Burris, H. A.
Jones, S. F.
Kolesar, J.
Gardner, L. R.
Sportelli, P.
Bendell, J. C.
机构：
[1] Sarah Cannon Res Inst, Nashville, TN USA
[2] Cannon Res Inst & Tennessee Oncol, Nashville, TN USA
[3] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[4] Keryx Biopharmaceut Inc, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e14086
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14086
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A POPULATION PHARMACOKINETIC (PK)-PHARMACODYNAMIC (PD) ANALYSIS OF AXITINIB (AG-013736) EFFICACY AND TOLERABILITY ENDPOINTS IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (mCRC).
    Tortorici, M. A.
    Tarazi, J.
    Ricart, A. D.
    Cartwright, T.
    Bendell, J. C.
    Sobrero, A. F.
    Infante, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S78 - S78
  • [42] A phase ib trial to evaluate the safety and efficacy of quinacrine plus capecitabine in patients with refractory metastatic colorectal cancer.
    Winer, Arthur
    Vijayvergia, Namrata
    Cohen, Steven J.
    Denlinger, Crystal S.
    Astsaturov, Igor A.
    Dotan, Efrat
    Gallant, Jean-Nicolas
    Wang, Edward W.
    Kunkel, Miriam
    Lim, Bora
    Harvey, Harold A.
    Sivik, Jeffrey Michael
    Zhou, Lanlan
    Korzekwa, Kenneth
    Ruth, Karen
    Ross, Eric A.
    El-Deiry, Wafik S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [43] A pharmacokinetic (PK) and safety study of sorafenib plus capecitabine in advanced solid tumors
    Mckay, C. E.
    Infante, J.
    Jones, S.
    Bendell, J.
    Greco, F. A.
    Markus, T. M.
    Spigel, D. R.
    Yardley, D. A.
    Woudenberg, J.
    Lathia, C. D.
    Burris, H. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [44] AZD6244 (ARRY-142886) versus capecitabine (CAP) in patients (pts) with metastatic colorectal cancer (mCRC) who have failed prior chemotherapy
    Lang, I.
    Adenis, A.
    Boer, K.
    Escudero, P.
    Kim, T.
    Valladares, M.
    Sanders, N.
    Pover, G.
    Douillard, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [45] Capecitabine and oxaliplatin (XELOX) as first-line treatment for elderly patients (pts) with advanced/metastatic colorectal cancer (MCRC)
    Salud, A.
    Escudero, P.
    Feliu, J.
    Lopez-Gomez, L.
    Bolanos, M.
    Galan, A.
    Yubero, A.
    Vicent, J. M.
    Losa, F.
    Gonzalez-Baron, M.
    EJC SUPPLEMENTS, 2005, 3 (02): : 190 - 190
  • [46] A phase Ib study of safety and clinical activity of atezolizumab (A) and cobimetinib (C) in patients (pts) with metastatic colorectal cancer (mCRC).
    Bendell, Johanna C.
    Bang, Yung-Jue
    Chee, Cheng Ean
    Ryan, David P.
    McRee, Autumn Jackson
    Chow, Laura Q.
    Desai, Jayesh
    Wongchenko, Matthew
    Yan, Yibing
    Pitcher, Bethany
    Foster, Paul
    Cha, Edward
    Grossman, William
    Kim, Tae Won
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [47] Bevacizumab (B) plus everolimus (E) in refractory metastatic colorectal cancer (mCRC)
    Bullock, K. E.
    Hurwitz, H. I.
    Uronis, H. E.
    Morse, M. A.
    Blobe, G. C.
    Hsu, S. D.
    Zafar, S. Y.
    Nixon, A. B.
    Howard, L. A.
    Bendell, J. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [48] Efficacy and safety findings from a phase II study of capecitabine (X) as first-line therapy in Japanese patients (pts) with advanced/metastatic colorectal cancer (MCRC).
    Shirao, K
    Doi, T
    Hatake, K
    Arai, Y
    Yamaguchi, K
    Hyodo, I
    Tamura, T
    Takemiya, S
    Takiuchi, H
    Sakata, Y
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 294S - 294S
  • [49] A phase I dose-escalation study of TAS-102 in patients (pts) with refractory metastatic colorectal cancer (mCRC).
    Patel, Manish R.
    Bendell, Johanna C.
    Mayer, Robert J.
    Benedetti, Fabio M.
    Rosen, Lee S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] Phase II trial of sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC)
    Cupini, S.
    Bursi, S.
    Masi, G.
    Loupakis, F.
    Barbara, C.
    Fornaro, L.
    Allegrini, G.
    Di Marsico, R.
    Andreuccetti, M.
    Falcone, A.
    EJC SUPPLEMENTS, 2007, 5 (04): : 251 - 251
12345